The feminization of HPV

How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation

Ellen M. Daley, Cheryl A. Vamos, Erika L. Thompson, Gregory Zimet, Zeev Rosberger, Laura Merrell, Nolan S. Kline

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal, vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on cervical cancer screening, women were identified as bearing the burden of HPV infection and its related illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This process must engage multiple stakeholders, including providers, parents, patients, professional organizations, public health agencies, policymakers, researchers, and community-based organizations.

Original languageEnglish (US)
Pages (from-to)142-148
Number of pages7
JournalPapillomavirus Research
Volume3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Feminization
Papillomavirus Vaccines
Politics
Economics
Uterine Cervical Neoplasms
Public Health
Condylomata Acuminata
Forensic Anthropology
Papillomavirus Infections
Marketing
Early Detection of Cancer
Parents
Research Personnel
Organizations
Morbidity
Mortality
Health

Keywords

  • Critical review
  • Feminization
  • HPV vaccination

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

The feminization of HPV : How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. / Daley, Ellen M.; Vamos, Cheryl A.; Thompson, Erika L.; Zimet, Gregory; Rosberger, Zeev; Merrell, Laura; Kline, Nolan S.

In: Papillomavirus Research, Vol. 3, 01.06.2017, p. 142-148.

Research output: Contribution to journalArticle

Daley, Ellen M. ; Vamos, Cheryl A. ; Thompson, Erika L. ; Zimet, Gregory ; Rosberger, Zeev ; Merrell, Laura ; Kline, Nolan S. / The feminization of HPV : How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. In: Papillomavirus Research. 2017 ; Vol. 3. pp. 142-148.
@article{8d49cfb600704b04a810ba78a7611989,
title = "The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation",
abstract = "Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal, vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on cervical cancer screening, women were identified as bearing the burden of HPV infection and its related illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This process must engage multiple stakeholders, including providers, parents, patients, professional organizations, public health agencies, policymakers, researchers, and community-based organizations.",
keywords = "Critical review, Feminization, HPV vaccination",
author = "Daley, {Ellen M.} and Vamos, {Cheryl A.} and Thompson, {Erika L.} and Gregory Zimet and Zeev Rosberger and Laura Merrell and Kline, {Nolan S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.pvr.2017.04.004",
language = "English (US)",
volume = "3",
pages = "142--148",
journal = "Papillomavirus Research",
issn = "2405-8521",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The feminization of HPV

T2 - How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation

AU - Daley, Ellen M.

AU - Vamos, Cheryl A.

AU - Thompson, Erika L.

AU - Zimet, Gregory

AU - Rosberger, Zeev

AU - Merrell, Laura

AU - Kline, Nolan S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal, vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on cervical cancer screening, women were identified as bearing the burden of HPV infection and its related illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This process must engage multiple stakeholders, including providers, parents, patients, professional organizations, public health agencies, policymakers, researchers, and community-based organizations.

AB - Human papillomavirus (HPV) can cause a number of anogenital cancers (i.e., cervical, penile, anal, vaginal, vulvar) and genital warts. A decade ago, the HPV vaccine was approved, and has been shown to be a public health achievement that can reduce the morbidity and mortality for HPV-associated diseases. Yet, the mistaken over-identification of HPV as a female-specific disease has resulted in the feminization of HPV and HPV vaccines. In this critical review, we trace the evolution of the intersection of science, politics, economics and gender norms during the original HPV vaccine approval, marketing era, and implementation. Given the focus on cervical cancer screening, women were identified as bearing the burden of HPV infection and its related illnesses, and the group responsible for prevention. We also describe the consequences of the feminization of HPV, which has resulted primarily in reduced protection from HPV-related illnesses for males. We propose a multilevel approach to normalizing HPV vaccines as an important aspect of overall health for both genders. This process must engage multiple stakeholders, including providers, parents, patients, professional organizations, public health agencies, policymakers, researchers, and community-based organizations.

KW - Critical review

KW - Feminization

KW - HPV vaccination

UR - http://www.scopus.com/inward/record.url?scp=85018969999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018969999&partnerID=8YFLogxK

U2 - 10.1016/j.pvr.2017.04.004

DO - 10.1016/j.pvr.2017.04.004

M3 - Article

VL - 3

SP - 142

EP - 148

JO - Papillomavirus Research

JF - Papillomavirus Research

SN - 2405-8521

ER -